Journal ArticleDOI
Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial
Reads0
Chats0
TLDR
Locally injected eASCs appear to be a simple, safe, and beneficial therapy for perianal fistula in Crohn’s disease patients, and additional studies are needed to further confirm the efficacy of the eASC.Abstract:
Purpose
The management of perianal fistula in patients with Crohn’s disease is an extremely challenging medical problem as many fistulas do not respond to available treatments The objectives were to assess the safety and efficacy of a suspension of expanded adipose-derived allogeneic mesenchymal stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s diseaseread more
Citations
More filters
Journal ArticleDOI
Stem cell transplantation for induction of remission in medically refractory Crohn’s disease
TL;DR: In this paper , the effects of stem cell transplantation compared to standard care alone or with placebo on efficacy and safety outcomes in patients with refractory Crohn's disease were evaluated.
Journal ArticleDOI
Mesenchymal stem cells for the treatment of complex perianal fistulas in patients with Crohn disease.
TL;DR: Current knowledge on the mechanisms of action and manner of administration of mesenchymal stem cells, as well as the effectiveness and safety of their use in the treatment of perianal Crohn's disease are presented based on available literature.
Book ChapterDOI
Autologous and Allogeneic Stem Cell Transplantation for Treatment of Crohn’s Fistulae
Fernando de la Portilla,Ana María García-Cabrera,Rosa M. Rodríguez‐Jiménez,Maria L. Reyes,Damián García-Olmo +4 more
TL;DR: The promising preclinical and clinical data suggest that cell therapy could represent a major advance in the clinical management of Crohn’s disease.
Journal ArticleDOI
One more chance of fistula healing in inflammatory bowel disease: Stem cell therapy.
TL;DR: These studies show stem cell therapy in fistulizing disease to be successful in healing between 60%-88% compared to currently 50% with infliximab, and remission was seen 24 wk to 52 wk in these studies.
Patent
Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
Eduardo Bravo,Maria Pascual +1 more
TL;DR: In this article, expanded allogeneic adipose tissue derived stromal stem cells for use in treating complex perianal fistulas in Crohn's Disease were used for the first time.
References
More filters
Journal ArticleDOI
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli
Massimo Di Nicola,Carmelo Carlo-Stella,Michele Magni,Marco Milanesi,Paolo Longoni,Paola Matteucci,Salvatore Grisanti,Alessandro M. Gianni +7 more
TL;DR: The data demonstrate that autologous or allogeneic BMSCs strongly suppress T-lymphocyte proliferation, this phenomenon that is triggered by both cellular as well as nonspecific mitogenic stimuli has no immunologic restriction, and T-cell inhibition is not due to induction of apoptosis and is likely due to the production of soluble factors.
Journal ArticleDOI
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more
TL;DR: Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Journal ArticleDOI
Human mesenchymal stem cells modulate B-cell functions
Anna Corcione,Federica Benvenuto,Elisa Ferretti,Debora Giunti,Valentina Cappiello,Francesco Cazzanti,Marco Risso,Francesca Gualandi,Giovanni Luigi Mancardi,Vito Pistoia,Antonio Uccelli +10 more
TL;DR: The results further support the potential therapeutic use of hMSCs in immune-mediated disorders, including those in which B cells play a major role.
Journal ArticleDOI
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.
TL;DR: Undifferentiated and differentiated MSC do not elicit alloreactive lymphocyte proliferative responses and modulate immune responses, and the findings support that MSC can be transplantable between HLA-incompatible individuals.
Journal ArticleDOI
Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.
Mauro Krampera,Sarah Glennie,Julian Dyson,Diane Scott,R. Laylor,Elizabeth Simpson,Francesco Dazzi +6 more
TL;DR: It is suggested that MSCs physically hinder T cells from the contact with APCs in a noncognate fashion and inhibit naive and memory T-cell responses to their cognate antigens.